Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood cancer and a leading cause of cancer-related mortality in children. Despite many major advances in the treatment of ALL, the emergence of therapy resistance and of therapy related complications remain significant challenges. Currently, about 2% of ALL patients are refractory to induction chemotherapy and 10-15% patients experience a relapse. The event-free survival of ALL patients with first relapse has not changed significantly for more than 20 years and remains poor at ~35-50%. Leukemia genomic data is vastly developing and makes new targets available.
New targeted therapy and immunotherapy are two important directions in the future to further improve the treatment result. Additionally, we must also look for new targeted therapy based on the current fast-developing leukemia genomic data, as well as looking for new immunotherapy strategies to focus on the relapsed and resistant leukemia.
We encourage prospective authors to focus their manuscripts on the initiatives around finding new mechanism for leukemia treatment resistance; developing new targeted therapy and/or immunotherapy to improve the leukemia treatment result and decrease the side effects.
Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood cancer and a leading cause of cancer-related mortality in children. Despite many major advances in the treatment of ALL, the emergence of therapy resistance and of therapy related complications remain significant challenges. Currently, about 2% of ALL patients are refractory to induction chemotherapy and 10-15% patients experience a relapse. The event-free survival of ALL patients with first relapse has not changed significantly for more than 20 years and remains poor at ~35-50%. Leukemia genomic data is vastly developing and makes new targets available.
New targeted therapy and immunotherapy are two important directions in the future to further improve the treatment result. Additionally, we must also look for new targeted therapy based on the current fast-developing leukemia genomic data, as well as looking for new immunotherapy strategies to focus on the relapsed and resistant leukemia.
We encourage prospective authors to focus their manuscripts on the initiatives around finding new mechanism for leukemia treatment resistance; developing new targeted therapy and/or immunotherapy to improve the leukemia treatment result and decrease the side effects.
